Carrie B Peltz1, Kimbra Kenney2, Jessica Gill2, Ramon Diaz-Arrastia2, Raquel C Gardner2, Kristine Yaffe2. 1. From San Francisco Veterans Affairs Health Care System (C.B.P., R.C.G., K.Y.), CA; Northern California Institute for Research and Education (C.B.P.), San Francisco; Uniformed Services University of the Health Sciences (K.K.), Rockville; NIH (J.G.), Bethesda, MD; Department of Neurology (R.D.-A.), University of Pennsylvania, Philadelphia; and Departments of Neurology (R.C.G., K.Y.), Psychiatry (K.Y.), and Epidemiology and Biostatistics (K.Y.), University of California, San Francisco. carrie.peltz@ncire.org. 2. From San Francisco Veterans Affairs Health Care System (C.B.P., R.C.G., K.Y.), CA; Northern California Institute for Research and Education (C.B.P.), San Francisco; Uniformed Services University of the Health Sciences (K.K.), Rockville; NIH (J.G.), Bethesda, MD; Department of Neurology (R.D.-A.), University of Pennsylvania, Philadelphia; and Departments of Neurology (R.C.G., K.Y.), Psychiatry (K.Y.), and Epidemiology and Biostatistics (K.Y.), University of California, San Francisco.
Abstract
OBJECTIVE: To determine whether blood-based biomarkers can differentiate older veterans with and without traumatic brain injury (TBI) and cognitive impairment (CogI). METHODS: We enrolled 155 veterans from 2 veterans' retirement homes: 90 without TBI and 65 with TBI history. Participants were further separated into CogI groups: controls (no TBI, no CogI), n = 60; no TBI with CogI, n = 30; TBI without CogI, n = 30; and TBI with CogI, n = 35. TBI was determined by the Ohio State University TBI Identification Method. CogI was defined as impaired cognitive testing, dementia diagnosis, or use of dementia medication. Blood specimens were enriched for CNS-derived exosomes. Proteins (neurofilament light [NfL], total tau, glial fibrillary acidic protein [GFAP], α-synuclein, β-amyloid 42 [Aβ42], and phosphorylated tau [p-tau]) and cytokines (tumor necrosis factor-α [TNF-α], interleukin-6 [IL-6], and interleukin-10) were measured using ultrasensitive immunoassays. RESULTS: Veterans were, on average, 79 years old. In participants with TBI history, 65% had mild TBI; average time from most recent TBI was 37 years. In adjusted analyses, the TBI and CogI groups differed on CNS-enriched exosome concentration of p-tau, NfL, IL-6, TNF-α (all p < 0.05), and GFAP (p = 0.06), but not on Aβ42 or other markers. Adjusted area under the curve (AUC) analyses found that all significantly associated biomarkers combined separated TBI with/without CogI (AUC, 0.85; 95% confidence interval [CI], 0.74-0.95) and CogI with/without TBI (AUC, 0.88; 95% CI, 0.77-0.99). CONCLUSIONS: Increased levels of blood-based, CNS-enriched exosomal biomarkers associated with TBI and CogI can be detected even decades after TBI. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that in veterans with a history of TBI, CNS-enriched exosome concentration of p-tau, NfL, IL-6, and TNF-α are associated with CogI.
OBJECTIVE: To determine whether blood-based biomarkers can differentiate older veterans with and without traumatic brain injury (TBI) and cognitive impairment (CogI). METHODS: We enrolled 155 veterans from 2 veterans' retirement homes: 90 without TBI and 65 with TBI history. Participants were further separated into CogI groups: controls (no TBI, no CogI), n = 60; no TBI with CogI, n = 30; TBI without CogI, n = 30; and TBI with CogI, n = 35. TBI was determined by the Ohio State University TBI Identification Method. CogI was defined as impaired cognitive testing, dementia diagnosis, or use of dementia medication. Blood specimens were enriched for CNS-derived exosomes. Proteins (neurofilament light [NfL], total tau, glial fibrillary acidic protein [GFAP], α-synuclein, β-amyloid 42 [Aβ42], and phosphorylated tau [p-tau]) and cytokines (tumor necrosis factor-α [TNF-α], interleukin-6 [IL-6], and interleukin-10) were measured using ultrasensitive immunoassays. RESULTS: Veterans were, on average, 79 years old. In participants with TBI history, 65% had mild TBI; average time from most recent TBI was 37 years. In adjusted analyses, the TBI and CogI groups differed on CNS-enriched exosome concentration of p-tau, NfL, IL-6, TNF-α (all p < 0.05), and GFAP (p = 0.06), but not on Aβ42 or other markers. Adjusted area under the curve (AUC) analyses found that all significantly associated biomarkers combined separated TBI with/without CogI (AUC, 0.85; 95% confidence interval [CI], 0.74-0.95) and CogI with/without TBI (AUC, 0.88; 95% CI, 0.77-0.99). CONCLUSIONS: Increased levels of blood-based, CNS-enriched exosomal biomarkers associated with TBI and CogI can be detected even decades after TBI. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that in veterans with a history of TBI, CNS-enriched exosome concentration of p-tau, NfL, IL-6, and TNF-α are associated with CogI.
Authors: Kimbra Kenney; Bao-Xi Qu; Chen Lai; Christina Devoto; Vida Motamedi; William C Walker; Harvey S Levin; Tracy Nolen; Elisabeth A Wilde; Ramon Diaz-Arrastia; Jessica Gill Journal: Brain Inj Date: 2018-06-11 Impact factor: 2.311
Authors: Deborah E Barnes; Amy L Byers; Raquel C Gardner; Karen H Seal; W John Boscardin; Kristine Yaffe Journal: JAMA Neurol Date: 2018-09-01 Impact factor: 18.302
Authors: Jessica Gill; Maja Mustapic; Ramon Diaz-Arrastia; Rael Lange; Seema Gulyani; Tom Diehl; Vida Motamedi; Nicole Osier; Robert A Stern; Dimitrios Kapogiannis Journal: Brain Inj Date: 2018-06-18 Impact factor: 2.311
Authors: Keisuke Kawata; Charles Y Liu; Steven F Merkel; Servio H Ramirez; Ryan T Tierney; Dianne Langford Journal: Neurosci Biobehav Rev Date: 2016-05-12 Impact factor: 8.989
Authors: Steven D Shirk; Meghan B Mitchell; Lynn W Shaughnessy; Janet C Sherman; Joseph J Locascio; Sandra Weintraub; Alireza Atri Journal: Alzheimers Res Ther Date: 2011-11-11 Impact factor: 6.982
Authors: William R McBride; Caroline E Conlan; Nicole A Barylski; Amelie C Warneryd; Randel L Swanson Journal: Curr Phys Med Rehabil Rep Date: 2022-02-26
Authors: David F Tate; Emily L Dennis; John T Adams; Maheen M Adamson; Heather G Belanger; Erin D Bigler; Heather C Bouchard; Alexandra L Clark; Lisa M Delano-Wood; Seth G Disner; Blessen C Eapen; Carol E Franz; Elbert Geuze; Naomi J Goodrich-Hunsaker; Kihwan Han; Jasmeet P Hayes; Sidney R Hinds; Cooper B Hodges; Elizabeth S Hovenden; Andrei Irimia; Kimbra Kenney; Inga K Koerte; William S Kremen; Harvey S Levin; Hannah M Lindsey; Rajendra A Morey; Mary R Newsome; John Ollinger; Mary Jo Pugh; Randall S Scheibel; Martha E Shenton; Danielle R Sullivan; Brian A Taylor; Maya Troyanskaya; Carmen Velez; Benjamin Sc Wade; Xin Wang; Ashley L Ware; Ross Zafonte; Paul M Thompson; Elisabeth A Wilde Journal: Brain Imaging Behav Date: 2021-01-07 Impact factor: 3.978
Authors: Samar Al-Hajj; Hassan R Dhaini; Stefania Mondello; Haytham Kaafarani; Firas Kobeissy; Ralph G DePalma Journal: Front Public Health Date: 2021-06-04
Authors: Raj G Kumar; Katherine A Ornstein; John D Corrigan; Rachel Sayko Adams; Kristen Dams-O'Connor Journal: J Neurotrauma Date: 2021-03-11 Impact factor: 4.869
Authors: Don Krieger; Paul Shepard; Ryan Soose; Ava M Puccio; Sue Beers; Walter Schneider; Anthony P Kontos; Michael W Collins; David O Okonkwo Journal: Med Sci (Basel) Date: 2021-03-25